Aim: To study effects of thrombolytic therapy in elderly patients.
Material And Methods: One hundred twenty three patients with acute myocardial infarction were admitted within first 12 hours of myocardial infarction, 66 of them were subjected to thrombolytic therapy with streptokinase (group 1) while 57 were not because of contraindications (group 2). In group 1 age of 49 patients was 66-75 years, and that of 17 patients exceeded 75 years.
Results: In 24.2% of patients pain ceased during thrombolysis. This effect occurred less often in patients over 75 years of age. Reperfusion arrhythmias were registered in 15.1% of older patients. Patients of group 2 more often had acute left ventricular failure (47.4% vs. 18.2% in group 1, p=0.003). Rate of development of acute heart failure was higher in patients aged over 75 years (by 8% compared with younger patients in both groups). Chronic heart failure developed in 36.8% and 13.6% of patients in group 2 and 1, respectively (p=0.001). Rate of chronic heart failure in group 1 was lower than among total population of patients, subjected to thrombolytic therapy (13.6 and 26.5%, respectively, p=0.040). Rate of early angina and reinfarction was higher in group 1 than in group 2 (by 4 and 3%, respectively). In 12 months rate of angina was higher in group 1 compared with group 2 (83.3 and 52.6%, respectively, p=0.088). Among patients with heart failure in group 1 prevailed those with class I-II (p=0.175) while in group 2 there were more patients with class III-IV than class I-II heart failure. Rate of chronic heart failure among patients older than 75 years was by 13 and 22.8% higher, than in younger patients of groups 1 and 2, respectively. One year mortality was 9.1% in group 1 and 22.8% (p=0.019) in group 2. Mortality among patients over 75 years of age was higher in both groups especially in group 1 (by 13.5%).
Download full-text PDF |
Source |
---|
Circ Res
January 2025
Hypertension Research Laboratory, School of Biological Sciences (R.R.M., T.Z., E.D., L.X., A.B.-W., H.A.J., M.N., M.P., K.C.L., W.Q., J.A.O.D., F.Z.M.).
Background: Fermentation of dietary fiber by the gut microbiota leads to the production of metabolites called short-chain fatty acids, which lower blood pressure and exert cardioprotective effects. Short-chain fatty acids activate host signaling responses via the functionally redundant receptors GPR41 and GPR43, which are highly expressed by immune cells. Whether and how these receptors protect against hypertension or mediate the cardioprotective effects of dietary fiber remains unknown.
View Article and Find Full Text PDFCirc Genom Precis Med
January 2025
Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands (S.L.V.M.S., N.J.B., M.F.G.H.M.V., V.P.M.v.E., J.A.J.V.).
Circ Heart Fail
January 2025
Department of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Denmark (S.G., J.H.T., J.J.T.).
Circ Heart Fail
January 2025
S.C. Medicina Generale 1, Medical Center, Ospedale di Circolo and Fondazione Macchi, Department of Internal Medicine, ASST Sette Laghi, Varese, Italy.
Circulation
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (Y.N.V.R., A.T., M.M.R., B.A.B.).
Background: Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) is commonly used to diagnose heart failure with preserved ejection fraction (HFpEF), but its diagnostic performance in the ambulatory/outpatient setting is unknown because previous studies lacked objective reference standards.
Methods: Among patients with chronic dyspnea, diagnosis of HFpEF or noncardiac dyspnea was determined conclusively by exercise catheterization in a derivation cohort (n=414), multicenter validation cohort 1 (n=560), validation cohort 2 (n=207), and a nonobese Japanese validation cohort 3 (n=77). Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!